Steven A. Grossman, JD, is President of HPS Group, LLC, a policy and regulatory consulting firm,  and author of  “FDA Matters: The Grossman FDA Report” (subscribe for free at https://www.fdamatters.com).

Mr. Grossman co-founded and later served as Executive Director of the Alliance for a Stronger FDA. This multi-stakeholder coalition has helped grow the FDA’s appropriated budget from $1.6 billion to $3.5 billion and deepened public understanding of the agency’s expanding responsibilities and budget needs. Under his direction, and as a response to the pandemic’s diminished public presence of senior FDA leaders, the Alliance ran more than fifty stakeholder webinars between 2021 and 2024.

Mr. Grossman’s advocacy is rooted in public service, having spent six years as Counsel and Health Staff Director on the Senate HELP Committee and four years as a Deputy Assistant Secretary for Health at HHS.

While in the Senate, he was one of the chief Senate negotiators on the Orphan Drug Act (ODA) and the Drug Price Competition and Patent Term Restoration Act (known as  Hatch-Waxman).

In recognition of his advocacy and policy leadership, he was awarded the Reagan-Udall Foundation for the FDA’s  Innovations in Regulatory Science Award in December 2024.